Multiple hypotheses assumed microglia could be restored to homeostatic states, but the debate didn't establish when this becomes impossible. This timing question is critical for early intervention strategies across all proposed mechanisms.
Source: Debate session sess_SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404 (Analysis: SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404)
Beyond 12 months human equivalent, conventional approaches fail due to irreversible epigenetic changes (DNA methylation of P2ry12 promoter, H3K27ac accumulation at disease-specific enhancers). Partial Yamanaka factor reprogramming could reset the epigenetic clock but carries oncogenic risk requiring careful titration.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations2 with PMIDValidation: 0%2 supporting / 3 opposing
✓For(2)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Oncogenic risk of OSKM delivery significant and unresolved
Regulatory path for partial reprogramming undefined
Delivery to microglia via AAV9 requires demonstration in aged brains
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-22 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic Hypotheses: Optimal Window for Microglial Reprogramming
Hypothesis 1: TREM2 Agonism Has a Narrow Early-Window Defined by Metabolic Transition Checkpoint
Title:The reversibility window for TREM2-targeted therapy closes at the DAM1→DAM2 transition
Mechanism: Microglia transition through defined states in neurodegeneration: homeostatic → intermediate (IFN response) → DAM1 (TREM2-dependent early stage) → DAM2 (lipid-processing, TREM2-independent late stage). We propose that TREM2 agonism can only revert DAM1 to homeostatic but cannot rescue DAM2 microglia, whic
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Microglial Reprogramming Therapeutic Window Hypotheses
Framework for Assessment
Before evaluating individual hypotheses, several overarching methodological concerns must be established:
General Weaknesses Across All Hypotheses:
Mouse-to-human translation uncertainty: The 5xFAD model's accelerated pathology timeline (months representing years of human disease) may not accurately map onto human therapeutic windows. The debate session does not address whether 2-4 month interventions in mice correspond to human clinical windows of weeks, months, or years.
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: Microglial Reprogramming Therapeutic Windows
Executive Summary
The seven hypotheses propose mechanistically distinct windows of intervention but share a common translational weakness: none define "irreversibility" with biochemical precision, and all rely on mouse model timelines that lack validated human correlates. After applying the skeptic's critiques and domain-specific evaluation criteria, four hypotheses warrant serious development investment (H1, H5, H7, H2), two represent high-risk/high-reward long-term bets (H4, H6), and **one is fundamentally ca
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "Metabolic Inflexibility Precedes Transcriptional Reprogramming (NAD+/SIRT3 Axis)", "description": "Mitochondrial dysfunction represents the earliest and most fundamental irreversibility checkpoint, preceding and driving transcriptional lock-in through NAD+ depletion and SIRT3 inactivation. This hypothesis offers the highest commercial tractability due to existing NR/NMN safety profiles and Phase I/II trials in metabolic indications.", "target_gene": "SIRT3/NAD+ salvage pathway, PGC-1α", "dimension_scores": { "evidence_s